Profusa, Inc. Common Stock Net Assets
Profusa, Inc. Common Stock net assets. Based on the latest financial reports, Profusa, Inc. Common Stock (PFSA) has net assets worth $-28.20 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($862.00K) and total liabilities ($29.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Profusa, Inc. Common Stock annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-28.20 Million |
| % of Total Assets | -3271.23% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of Profusa, Inc. Common Stock (2021–2025)
Net assets of Profusa, Inc. Common Stock from 2021 to 2025. This chart illustrates how Profusa, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See net asset quality index of Profusa, Inc. Common Stock to measure how much of total assets are equity-financed.
Annual Net Assets for Profusa, Inc. Common Stock (2021–2025)
The table below shows the annual net assets of Profusa, Inc. Common Stock from 2021 to 2025. For live market cap and overall valuation, see Profusa, Inc. Common Stock (PFSA) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-26.66 Million | +77.64% |
| 2024-12-31 | $-119.20 Million | -8.37% |
| 2023-12-31 | $-110.00 Million | -10.25% |
| 2022-12-31 | $-99.77 Million | -19.26% |
| 2021-12-31 | $-83.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Profusa, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7555100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Profusa, Inc. Common Stock Net Assets Breakdown (December 2025)
Profusa, Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $134.12 Million | % |
| Total Equity | $-26.66 Million | 100.00% |
Profusa, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Profusa, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Medivie Therapeutic Ltd
TA:MDVI
|
$371.77K |
|
ALBERT LABS INTL. CORP.
F:VB50
|
$372.07K |
|
PROPHECY DEFI INC.
F:V8M
|
$374.62K |
|
GeoVax Labs Inc
NASDAQ:GOVX
|
$374.90K |
|
LIVE MOTION GAMES ZY -10
F:4YM
|
$370.80K |
|
Hemogenyx Pharmaceuticals PLC
LSE:HEMO
|
$369.21K |
|
Yuilrobotics Co. Ltd.
KQ:388720
|
$368.42K |
|
Carclo plc
LSE:CAR
|
$366.25K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Profusa, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -119,205,000 to -26,658,000, a change of 92,547,000.
- Net loss of 35,823,000 reduced equity.
- Other factors increased equity by 128,370,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-35.82 Million | -134.38% |
| Other Changes | $128.37 Million | +481.54% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Profusa, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-259.60 | $0.70 | x |
| 2022-12-31 | $-309.61 | $0.70 | x |
| 2023-12-31 | $-820.05 | $0.70 | x |
| 2024-12-31 | $-4612.48 | $0.70 | x |
| 2025-12-31 | $-79.63 | $0.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Profusa, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.94 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.24 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $718.60K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $2.69 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-33.16 Million |
Industry Comparison
This section compares Profusa, Inc. Common Stock's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $4,918,430,339
- Average return on equity (ROE) among peers: -76.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Profusa, Inc. Common Stock (PFSA) | $-28.20 Million | 0.00% | N/A | $371.00K |
| Abbott Laboratories (ABT) | $47.90 Billion | 27.98% | 0.70x | $184.67 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $2.26 Million |
| Aethlon Medical Inc (AEMD) | $-2.20 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-225.81 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $1.47 Billion | -46.29% | 2.07x | $786.82 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $2.17 Million |
| Allurion Technologies, Inc. (ALUR) | $19.83K | -26.07% | 15.64x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $1.96 Million | -680.21% | 0.05x | $1.76 Million |
| Artivion Inc (AORT) | $20.50 Million | 10.73% | 0.15x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $18.79 Million | 9.75% | 0.37x | $109.52 Million |
About Profusa, Inc. Common Stock
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platf… Read more